We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

130 hedge funds and large institutions have $243M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 65 increasing their positions, 24 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 24

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

5% more funds holding

Funds holding: 124 → 130 (+6)

36% less capital invested

Capital invested by funds: $378M → $243M (-$135M)

80% less call options, than puts

Call options by funds: $340K | Put options by funds: $1.73M

Holders
130
Holders Change
+6
Holders Change %
+4.84%
% of All Funds
2.26%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
20
Increased
65
Reduced
24
Closed
14
Calls
$340K
Puts
$1.73M
Net Calls
-$1.39M
Net Calls Change
+$1.24M

Top Buyers

Rank Fund Capital Flow
1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$5.67M
2
BlackRock
BlackRock
New York
+$5.13M
3
CS
Candriam SCA
Luxembourg
+$2.8M
4
O
OrbiMed
New York
+$2.69M
5
Millennium Management
Millennium Management
New York
+$2.33M

Top Sellers

Rank Fund Capital Flow
1
TGI
TRV GP II
Massachusetts
-$17.1M
2
Victory Capital Management
Victory Capital Management
Texas
-$15.4M
3
CCM
CAAS Capital Management
New York
-$10.8M
4
ACA
Avoro Capital Advisors
New York
-$5.7M
5
ACM
Asymmetry Capital Management
California
-$5.35M
Name Holding Trade Value Shares
Change 		Change in
Stake
KAS
76
Kestra Advisory Services
Texas
$173K -$8 -1 -0%
CAPTRUST Financial Advisors
77
CAPTRUST Financial Advisors
North Carolina
$167K +$24.9K +3,000 +14%
EGM
78
Engineers Gate Manager
New York
$167K +$204K +24,500 New
HF
79
HRT Financial
New York
$151K -$164K -19,711 -47%
HTC
80
Hershey Trust Company
Pennsylvania
$149K +$100K +12,058 +122%
Axa
81
Axa
France
$137K -$395K -47,600 -70%
Deutsche Bank
82
Deutsche Bank
Germany
$133K +$69.4K +8,355 +74%
FIM
83
Fernwood Investment Management
Massachusetts
$131K +$53K +6,377 +50%
MGB
84
Mass General Brigham
Massachusetts
$131K +$160K +19,291 New
GC
85
Grace Capital
Massachusetts
$127K +$49.4K +5,941 +47%
UBS Group
86
UBS Group
Switzerland
$125K -$8.82K -1,062 -5%
ProShare Advisors
87
ProShare Advisors
Maryland
$121K +$57.2K +6,882 +63%
MSAM
88
Moloney Securities Asset Management
Missouri
$113K -$24.9K -3,000 -15%
HSA
89
Hussman Strategic Advisors
Maryland
$105K +$129K +15,500 New
PP
90
PDT Partners
New York
$102K +$22.2K +2,674 +22%
Bank of America
91
Bank of America
North Carolina
$90K -$141K -16,939 -56%
FT
92
Fiduciary Trust
Massachusetts
$90K +$110K +13,230 New
FWM
93
Frontier Wealth Management
Missouri
$89K – – –
Susquehanna International Group
94
Susquehanna International Group
Pennsylvania
$82K -$83.2K -10,014 -45%
NA
95
Navellier & Associates
Nevada
$82K -$764 -92 -0.8%
HFS
96
Horizon Financial Services
North Carolina
$82K – – –
SO
97
STRS Ohio
Ohio
$82K – – –
AA
98
Advisory Alpha
Michigan
$82K +$99.7K +12,005 New
Bessemer Group
99
Bessemer Group
New Jersey
$81K – – –
PPA
100
Parametric Portfolio Associates
Washington
$79K -$1.73K -208 -2%
2 3
4
5 6

JNCE Hedge Fund Activity: Q2 2021 in Review

130 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q2 2021, worth a combined $243M — down 36% from $378M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new JNCE positions and 14 closed out — a net gain of 6 holders — while 65 added to existing stakes and 24 trimmed.

The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $5.67M. The largest seller was TRV GP II, cutting an estimated $17.1M.

  • 130 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q2 2021, up from 124 in Q1 2021.
  • Funds reported $243M of Jounce Therapeutics, Inc. Common Stock stock for Q2 2021, down 36% quarter-over-quarter.
  • 20 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q2 2021 and 14 closed out, a net change of +6 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q2 2021 was Assenagon Asset Management, an estimated $5.67M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q2 2021 was TRV GP II, an estimated $17.1M sold.

Based on aggregated 13F filings for Q2 2021.